Insulin and related factors in premenopausal breast cancer risk

Breast Cancer Research and Treatment

Volumn 47, Issue 2, 1998, Pages 111-120

  Del Giudice, M Elisabeth ^a,c   Fantus, I George ^a   Ezzat, Shereen ^a,b   McKeown Eyssen, Gail ^a   Page, David ^d   Goodwin, Pamela J ^a,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d VANDERBILT UNIVERSITY   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Breast cancer; Insulin; Premenopausal risk

Indexed keywords

INSULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; PREMENOPAUSE; RISK FACTORS;

EID: 0031984686     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005831013718     Document Type: Article

References (38)

1. Bruning PF, Bonfrer JMG, Van Nooyrd PAH, Hart AAM, De Jong-Bakker M, Nooijen WJ: Insulin resistance and breast cancer risk. Int J Cancer 52: 511-516, 1992
2. Repert RW: Breast cancer: Relation to thyroid disease and diabetes. J Michigan State M Soc 52: 1315-1320, 1952
3. Lancaster HO, Maddox JK: Diabetic mortality in Australia. Austr Ann Med 7: 145-151, 1958
4. Unger C, Rageth JC, Wyss P: Risk factors in breast carcinoma. J Suisse Med 121: 30-36, 1991
5. Glicksman AS, Myers WPL, Rawson RW: Diabetes mellitus and carbohydrate metabolism in patients with cancer. Med Clin N Amer 40: 887-900, 1956
6. Muck BR, Trotnow S, Hommel G: Cancer of the breast, diabetes and pathological glucose tolerance. Arch Gynak 220: 73-81, 1975
7. Barker BE, Fanger H, Farnes P: Human mammary slices in organ culture. I. Methods of culture and preliminary observations on the effects of insulin. Exp Cell Res 35: 437-448, 1964
8. Elias JJ, Armstrong RC: Hyperplastic and metaplastic responses of human mammary fibroadenomas and dysplasias in organ culture. J Natl Cancer Inst 51: 1341-1343, 1973
9. Dideriksen LH, Jorgensen LN, Drejer K: Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 41 (Suppl 1): 143A, 1992
10. Giogino F, Belfiore A, Milazzo G, Costantino A, Maddux B, Whittaker J et al.: Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol 5: 452-459, 1991
11. Kaleko M, Rutter WJ, Miller AD: Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 10:464-473, 1990
12. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C et al.: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512, 1986
13. Goodwin PJ, Boyd NF, Hanna W, Hartwick W, Murray D, Qizilbash A, Redwood S, Hood N, Del Guidice NE, Sidlofsky S, McCready D, Wilkinson R, Mahoney L, Connelly P, Page D: Elevated levels of plasma triglycerides are associated with premenopausal breast cancer risk. Nutr Cancer 27: 284-292, 1997
14. Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312: 146-151, 1985
15. Block G, Hartman A, Dresser CM, Carroll MD, Cannon J, Gardner L: A data based approach to diet questionnaire design and testing. Am J Epidemiol 86: 453-469, 1986
16. Ezzat S, Song-Guang R, Braunstein GD, Melmed S: Octreotide stimulates insulin-like growth factor binding protein-1: A potential pituitary independent mechanism for drug action. J Clin Endocrinol Metab 75: 1459-1463, 1992
17. SAS Institute Inc.: SAS/STAT user's guide, version 6.09. Cary, NC: SAS Institute Inc. (1989)
18. Hill DJ, Milner RDG: Insulin as a growth factor. Pediatr Res 19: 879-886, 1985
19. Straus DS: Growth-stimulatory actions of insulin in vitro and in vivo. Endocrinol Rev 5: 356-369, 1984
20. Straus DS: Effects of insulin on cellular growth and proliferation. Life Sci 29: 2131-2139, 1981
21. Webster NJG, Resnik JL, Reichart DB, Strauss B, Haas M, Ceely BL: Repression of the insulin receptor promotor by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res 36: 2781-2788, 1996
22. Zapf J, Schoenle E, Froesch ER: Insulin-like growth factors I and II: some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin-like activity of human serum. Eur J Biochem 87: 285-296, 1978
23. Lammers R, Gray A, Schlessinger J, Ullrich A: Differential signalling potential of insulin- and IGF-I receptor cytoplasmic domains. EMBO J 8: 1369-1375, 1989
24. Holdaway IM, Friesen HG: Hormone binding by human mammary carcinoma. Cancer Res 37: 1946-1952, 1977
25. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L et al.: Elevated insulin receptor content in human breast cancer. J Clin Invest 86: 1503-1510, 1990
26. Cullcn KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME et al.: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50: 48-53, 1990
27. Foekens JA, Portengen H, Janssen M, Klijn JGM: Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63: 2139-2147, 1989
28. Pekonen F, Partanen S, Makinen T, Rutanen EM: Receptors for epidermal growth factor and insulin-like growth factor 1 and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343-1347, 1988
29. Peyrat JP, Bonneterre J, Beauscart R, Dijane J, Demaille A: Insulin-like growth factor I receptors (IGF1-R) in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 48: 6429-6433, 1988
30. Ursin G, Longnecker MP, Haile RW: A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiol 6: 137-141, 1995
31. Le Marchand LL, Kolonel LN, Earle ME, Mi MP: Body size at different periods of adult life and breast cancer risk. Am J Epidemiol 128: 137-152, 1988
32. Moller DE, Flier JS: Insulin resistance-mechanisms, syndromes and implications. N Engl J Med 325: 938-948, 1991
33. Zimmet PZ, Collins VR, Dowse GK, Alberti KG: The relation of physical activity to cardiovascular disease risk factors in Mauritians. Mauritius Noncommunicable Disease Study Group. Am J Epidemiol 134: 862-875, 1991
34. Reitman JS, Vasquez B, Klimes Z et al.: Improvement of glucose homeostasis after exercise training in non-insulin dependent diabetes. Diabetes Care 7: 434-441, 1984
35. Steiner G: Hyperinsulinaemia and hypertriglyceridemia. J Intern Med 736 (Suppl): 23-26, 1994
36. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C et al.: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A: 492-497, 1993
37. Bruning PF, Vandoorn J, Bonfrer JMG, Van Noord PAH, Korse CM, Linders TC et al.: Insulin-like growth factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int J Cancer 62: 266-270, 1995
38. Baxter RC, Martin JL: Regulation and actions of insulin-like growth factor binding protein-3. Adv Exp Med Biol 293: 125-131, 1991